HANSOH PHARMACEUTICAL GROUP

Hansoh Pharma falls 7.33% as Roche licensing and positive ESMO data buoy investor optimism – find the latest price, market cap and trend insights.

Hansoh Pharmaceutical drops 7.33% as China‑based pharma faces a sharp pullback. The 200‑day SMA remains support, and a rebound could be fueled by new trials and partnerships.

Hansoh Pharma’s 8.3% rally powers ahead, boosted by a Roche ADC deal that could bring $10B+ milestones and global clinical reach.

Hansoh Pharmaceutical’s HKD 34.38 share price climbs 1.15% as 24‑hour volume hits HKD 333.4M, amid a 7.57% monthly decline and 52‑week swing.